Impact of abciximab in elderly patients with high-risk acute coronary syndrome undergoing percutaneous coronary intervention: an observational registry study

Allan Z Iversen; Soeren Galatius; Sune Ammentorp Haahr-Pedersen; Jan K Madsen; Jan S Jensen

doi:10.2165/11587170-000000000-00000

Impact of abciximab in elderly patients with high-risk acute coronary syndrome undergoing percutaneous coronary intervention: an observational registry study

Allan Z Iversen, Soeren Galatius, Sune Ammentorp Haahr-Pedersen, Jan K Madsen, Jan S Jensen

3 Citations (Scopus)

Abstract

Background: An increasing proportion of patients with acute coronary syndrome (ACS) requiring percutaneous coronary intervention (PCI) are classified as elderly (aged ≥70 years). The glycoprotein IIb/IIIa inhibitor abciximab is known to reduce adverse outcomes in patients aged

Original language	English
Journal	Drugs & Aging
Volume	28
Issue number	5
Pages (from-to)	369-78
Number of pages	10
ISSN	1170-229X
DOIs	https://doi.org/10.2165/11587170-000000000-00000
Publication status	Published - 1 May 2011

Access to Document

10.2165/11587170-000000000-00000

Cite this

Impact of abciximab in elderly patients with high-risk acute coronary syndrome undergoing percutaneous coronary intervention: an observational registry study. / Iversen, Allan Z ; Galatius, Soeren; Haahr-Pedersen, Sune Ammentorp et al.
In: Drugs & Aging, Vol. 28, No. 5, 01.05.2011, p. 369-78.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{d4c572defe954a87bf71faabdcb71ce3,

title = "Impact of abciximab in elderly patients with high-risk acute coronary syndrome undergoing percutaneous coronary intervention: an observational registry study",

abstract = "Background: An increasing proportion of patients with acute coronary syndrome (ACS) requiring percutaneous coronary intervention (PCI) are classified as elderly (aged ≥70 years). The glycoprotein IIb/IIIa inhibitor abciximab is known to reduce adverse outcomes in patients aged ",

author = "Iversen, \{Allan Z\} and Soeren Galatius and Haahr-Pedersen, \{Sune Ammentorp\} and Madsen, \{Jan K\} and Jensen, \{Jan S\}",

year = "2011",

month = may,

day = "1",

doi = "10.2165/11587170-000000000-00000",

language = "English",

volume = "28",

pages = "369--78",

journal = "Drugs \& Aging",

issn = "1170-229X",

publisher = "Adis",

number = "5",

}

TY - JOUR

T1 - Impact of abciximab in elderly patients with high-risk acute coronary syndrome undergoing percutaneous coronary intervention: an observational registry study

AU - Iversen, Allan Z

AU - Galatius, Soeren

AU - Haahr-Pedersen, Sune Ammentorp

AU - Madsen, Jan K

AU - Jensen, Jan S

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Background: An increasing proportion of patients with acute coronary syndrome (ACS) requiring percutaneous coronary intervention (PCI) are classified as elderly (aged ≥70 years). The glycoprotein IIb/IIIa inhibitor abciximab is known to reduce adverse outcomes in patients aged

AB - Background: An increasing proportion of patients with acute coronary syndrome (ACS) requiring percutaneous coronary intervention (PCI) are classified as elderly (aged ≥70 years). The glycoprotein IIb/IIIa inhibitor abciximab is known to reduce adverse outcomes in patients aged

UR - https://www.scopus.com/pages/publications/79955696682

U2 - 10.2165/11587170-000000000-00000

DO - 10.2165/11587170-000000000-00000

M3 - Journal article

C2 - 21542659

SN - 1170-229X

VL - 28

SP - 369

EP - 378

JO - Drugs & Aging

JF - Drugs & Aging

IS - 5

ER -

Impact of abciximab in elderly patients with high-risk acute coronary syndrome undergoing percutaneous coronary intervention: an observational registry study

Abstract

Access to Document

Other files and links

Fingerprint

Cite this